BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...In a human RCC cell line, the compound inhibited growth with greater potency than the CSNK2 inhibitor...
...protein kinase CSNK2 inhibitor, in Phase II testing for biliary cancer. Curtana Pharmaceuticals Inc. has a CSNK2 inhibitor...
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...xenograft mouse model (see Distillery ). Senhwa Biosciences Inc. (TPEx: 6492) has CX-4945, an oral CSNK2 inhibitor...
...said that because invading cells are typically not proliferating cells, and vice versa, using a CSNK2 inhibitor...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...vector. In three additional patient-derived GBM cell lines co-cultured with the mouse brain slices, the CSNK2 inhibitor...
BioCentury | Oct 23, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Myelodysplastic syndrome (MDS) Casein kinase 1 (CSNK1; CKI) In vitro and mouse studies suggest inhibiting CSNK1 could help treat MDS. Deletion of the long arm...
Items per page:
1 - 4 of 4